Feasibility Study of Sleep Endoscopy Under Hypnosis in a Sleep Center

NCT ID: NCT05091164

Last Updated: 2021-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-08

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is proposed to induce in a obstructive sleep apnea syndrome patient, a hypnotic trance leading to intense muscle relaxation, capable of reproducing in the upper airways (VAS) the muscle relaxation observed in sleep, at the origin of obstructive apnea and snoring. The collapsibility type obtained, classified according to Kezirian, will allow specific management by OAM in the event of predominant anteroposterior stenosis. There are no risks fort the patient. The Drug Induce Sleep endoscopy (DISE) is a fibroscopy of upper aerodigestive tract.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Induce Sleep Endoscopy Hypnosis Obstructive Sleep Apnea Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moderate obstructive sleep apnea syndrome patient under hypnosis

Patients suffering from moderate obstructive sleep apnea syndrome. It is proposed to induce in the patient a hypnotic trance leading to intense muscle relaxation, capable of reproducing in the upper airways.

The type of collapsibility thus obtained, classified according to Kezirian (6), will allow specific management by OAM in the event of predominant anteroposterior stenosis.

Group Type EXPERIMENTAL

Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis

Intervention Type PROCEDURE

Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis

Drug induce sleep endoscopy of upper aerodigestive tract under hypnosis.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient, women or men over 18 years old
* Moderate obstructive sleep apnea syndrome (Hypopnea apnea index between 15 and 30) without any serious sign
* Simple Ronchopathy
* Indication of video-fibroscopy of upper airways
* Affiliated subject or beneficiary of a social security scheme
* Patient having signed the free and informed consent

Exclusion Criteria

* Psychiatric disorders that can be decompensated by hypnosis (bipolarity, schizophrenia, ...)
* Smoking less than 10 cigarettes per day
* Alcoholism, chronic or serious disabling pathology
* Medical history of cancer of upper airways, radiotherapy
* Pregnancy
* Recent supper airway infection, rhinosinusitis
* Active allergy
* Non-obstructive sleep apnea syndrome
* severe non-obstructive sleep apnea syndrome (Hypopnea apnea index\> 30)
* Dental contraindication to mandibular advancement device
* Intolerance or allergy to local anesthesia with Xylocaine spray 5% known
* Refusal to participate in the study
* Protected patients: adults under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
* Pregnant, breastfeeding or parturient woman
* Hospitalized without consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Clinical Trial Experts Network

OTHER

Sponsor Role collaborator

Polyclinique Poitiers

UNKNOWN

Sponsor Role collaborator

Elsan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre du Sommeil de la Polyclinique de Poitiers

Potiers, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A02419-30

Identifier Type: -

Identifier Source: org_study_id